1 active not recruiting, 1 enrolling by invitation. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Dementia, Mild: new trials by email Literature Review of Dementia, Mild trials Research Report on Dementia, Mild
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tau PET Outcomes With Anti-amyloid Immunotherapies 18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild | Phase 2 | Enrolling by invitation | Mayo Clinic | 135 | 2025-11-04 | 2026-10-30 |
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
Alzheimer Disease (2) · Dementia (2) · Lymphoma, Follicular (2) · Cognitive Dysfunction (1)
Brain Diseases (2) · Central Nervous System Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Mental Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2)
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · UE2343 (1)
Actinogen Medical (1) · Mayo Clinic (1)
United States (2) · Australia (1)